ALEMBIC PHARMA -Q1 FY 21 - RESULTS REVIEW

ALEMBIC PHARMA Q1 FY 21 RESULTS REVIEW

Alembic Pharmaceuticals Limited reported its consolidated financial  results for the quarter ending 301h June 2020. 

Financial Highlights for Q1 FY21 

•  Net Sales up 41 % to Rs 1341  crores

•  Profit before tax up 131 % to Rs 368 crores

•  Net Profit up 144% to Rs 301  crores 

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said-

 "It was an  excellent quarter for the company backed  by growth  in  all  the international  markets.  Despite exceptionally, challenging  circumstances,  the operating teams ensured profitability and growth." 

Operational Highlights 

International Business 

•  International formulations grew 70% to Rs 771  crores in the quarter.

•  US Generics grew 73% to Rs 596 crores in the quarter.

 •  Ex-US International Formulations grew 62% to Rs 175 crores in the quarter.

•  6 ANDA approvals received during the quarter,  Cumulative ANDA approvals at 125 (including 14 tentative).

•  8 ANDA filings during the quarter;  Cumulative ANDA filings at 191.

India Formulations Business 

•  India formulations business for the quarter de-grew by 6% to Rs 306 crores

Summary of Total Revenue is as under (Rs in Crores)

 

Particulars     Q1  FY20 : Q1  FY19 :  % Change 

Formulation

USA               596        345        73%

EX-USA         175        108        62%

India             306        324        -6%

API               264        172        54%

Total             1341      949        41%

The Profit break-up is as under: (Rs in Crores) 

Particulars           Q1  FY20       Q1  FY19       % Change EBITDA                    416        200        108% 

EBITDA%                31%          21%

Profit Before Tax       368        160        131%

after Exceptional Items

Net Profit after Tax     301       124          144

About Alembic Pharmaceuticals Limited

Alembic  Pharmaceuticals  Limited,  a  vertically  integrated  research  and  development pharmaceutical company,  has been at the forefront of healthcare since 1907.  

Headquartered in  India,  Alembic  is  a  publicly  listed  company  that manufactures  and  markets  generic pharmaceutical  products  all  over  the  world.  

Alembic's  state  of the  art  research  and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. 

Alembic is one of the leaders in branded generics in India.

Alembic's brands,  marketed through a marketing team of over 5000 are well recognized by doctors and patients.

FINANCIAL HIGH LIGHTS (INR BNS)

Particulars           Q1 FY21 Q1 FY20  Growth YTD FY20

Net Sales             13.41     9.49        41%     46.06

EBIDTAPre R&D    5.49       3.3         166%    18.15

Margin %             41%       35%         39%

R&D                     1.41       1.39           2%     6.45

R&D %                 11%       15%                    14%

EBIDTA Post R&D 4.16       2.00       108%      12.13

Margin %             31%       21%        26%

Net Profit             3.01       1.24       144%       8.29

Capex                  1.42       1.7         46.97

Debt‐Equity (Net) 0.33       0.35       0.52

Well‐established US front end having strong customer base

Expanded our capabilities to deliver a diverse portfolio to the US market

72 products launched through the US front end (3 launched in Q1FY21), 7 products are on partner label

5 products planned to be launch in Q2FY21

Ex‐US driven by partnership

Presence in following markets‐ Europe, Canada, Australia, Brazil and South Africa

The business will focus on new launches across key markets

Plant successfully audited by key regulatory authorities across the globe

APIs

Sales across geographies as preferred supplier

Investing in plants to create additional capacities

FDA Compliant plants

State of the art R&D center and Process development lab

109 DMF filings on cumulative basis

R&D CAPABILITIES

Formulation:Vadodara, Hyderabad and USA API:Vadodara and Hyderabad

Bio Centre    :Vadodara

1200+ R&D employees with diverse skill SETS

11 Filings &7 Approvals were contributed by acquisition of Orit,US in FY18

ALEMBIC PHARMA - RESULTS - FOR Q1 FY 2014-15 - (jUNE 14) - Net Sales up 16%; Net Profits up 39% YoY - 35 APPROVED ANDAs - future looks promising

ALEMBIC PHARMACEUTICALS LIMITED

RESULTS FOR Q1 FY 2015

JUNE 2014

ALEMBIC PHARMA has done well in Q1 FY 15 ending June 2014.

Net Sales have gone by 7% QoQ and 16% YoY.

Net Profit has gone up by 5.51% QoQ and 38.66% YoY. Thus, both sequentially and Year on Year, Alembic Pharma has scored well in Q1 FY 15.

The EBITDA margins also have improved to 19.5% from 16.7% YoY.

Totally, 35 ANDA applications have received approvals so far – including 3 in Q1.

Total ANDA filings are 64 including 3 in Q1.

Alembic’s state of the Art Manufacturing facilities are approved by regulatory authorities  all over the world including US FDA.

Alembic Pharma is progressing impressively in terms of both sales and Net Profits.

TABLE OF RESULTS

Alembic Pharma	Q1FY15	Q4FY14	Dif%QoQ	Q1FY14	Dif%YoY	FY14
Net Sales	493.65	463.33	6.54	426.59	15.72	1860.7
Net Income	494.28	464.03	6.52	427.16	15.71	1863.21
OPT	96.67	91.29	5.89	71.48	35.24	357.71
PBT	84.93	80.78	5.14	60.5	40.38	310.5
NPT	64.67	61.29	5.51	46.64	38.66	235.5
EPS	3.43	3.25	5.54	2.47	38.87	12.49
EQ(FV Rs.2)	37.7

*  *  *  E  N  D  *  *  *

ALEMBIC PHARMACEUTICALS - RESULTS -Q4 & FY 14 - NET SALES UP 23% YoY; NET PROFIT UP 40% YoY

ALEMBIC PHARMACEUTICALS LTD

RESULTS FOR Q4 & FY 14

HIGHLIGHTS FOR Q4 FY14

Ø  Net sales up by 23% to Rs.456.28 Cr against Rs.378 Cr in Q4 FY 13.

Ø  Profit from Operations stands at Rs.91.29 cr; against Rs.65.58 cr in Q4 FY 13.

Ø  Profits Before Tax up by 46% to Rs.81 Cr against Rs.58 Cr in Q4 FY 13

Ø  Net Profit after Tax up by 40% to Rs.61.3 cr against Rs.43.7 cr in Q4 FY 13.

Ø  EBITDA margins is 19.6% at rs.91.3.cr against Rs.65.6 Cr in Q4 FY 13.

Ø  Paid up Equity stands at  Rs.37.70 Cr.

Ø  Basic EPS stands at Rs.3.25 against a Face Value of Rs.2. – against Rs.3.5 in previous quarter and Rs.2.32 in Q4 FY 13.

Year Ended 31^st March 2014

Ø  Net Sales up by 22% to Rs.1868.4 cr against Rs.1526 cr last year.

Ø  Profit from Operations stands at Rs.358 cr against Rs.252 cr Last Year.

Ø  Profit Before Tax up by 51% to Rs.310.6 Cr against Rs.206.4 Cr last year.

Ø  Net Profit After Tax up by 43% to Rs.235.5 Cr against Rs.165.3 cr last year.

Ø  EBITDA margins is 19.2% at Rs.357.7 Cr against 16.5% at rs.252 cr last year.

Ø  Basic EPS stands at Rs.12.49 against Rs.8.77 cr last year (on a FV of Rs.2)

Ø  The Board has recommended Dividend at Rs.3 per share or 150% for FY 14 against Rs.2.50 or 125% per share last year.

Ø  The India Branded Formulations Business posted Sales of Rs.199.5 Cr against Rs.175.3 Cr with a 14% growth over Q4 FY 13.

Ø  The India Branded Formulations Business posted Sales for Year ended 31-03-2014 of Rs.850.6 Cr against Rs.748.4 Cr with a 14% growth over the previous year.

Ø  As per ORG IMS, Alembic has market share of 1.73% (MAT-Mar 14). Gestofit has featured as company’s 5^th brand in top 300 Brands list of IMS-ORG.

Ø  Specialty and Acute segments grew by 17% and -3% respectively in current years (MAT – Mar 14) versus Industry average growth rate of 11% and 3% respectively.

INTERNATIONAL GENERICS

Ø  International Generics formulation posted growth of 76% and posted sales of Rs.136.7 crores against Rs.77.7 Cr over Q4 FY 13.

Ø  International Generics formulation posted Sales for the year FY 14 of Rs.468.4 crores against Rs.235.8 Cr with a 99% Growth over FY 13.

Ø  During Q4, 1 ANDA application and for the year 4 ANDA applications were filed taking cumulative ANDA  filings of the company to 61.

Ø  During the quarter, 1 ANDA approval and for the year 8 ANDA approvals were received taking cumulative  ANDA/NDA approvals to 32 (including 4 tentative approvals). During the quarter, 2 DMF applications and for the year 6 DMF applications were filed taking cumulative DMF filings of the company to 66.

About Alembic Pharma

A vertically integrated R&D Pharma co. Manufactures and markets  Generic Pharma products all over the world.  Its state of the Art research & Manufacturing facilities  are approved by US FDA and other regulatory authorities. Alembic’s brands, marketed through a marketing team of over 4000 are well recognized .  

Alembic Pharma has been  progressing well quarter after quarter. Its R&D is strong and is producing Generic Pharma Products  regularly. It is therefore a good BUY for medium / Long term Investors.

*  *  * E  N  D  *  *  *